Blood knowhow wins German Red Cross Kiadis contract ahead of CMOs

By Gareth Macdonald

- Last updated on GMT

Related tags Immune system

Blood knowhow wins German Red Cross Kiadis contract
Kiadis Pharma has called on the German Red Cross to make its candidate cancer treatment ahead of contractors with less experience of manufacturing blood-derived products.

The deal - financial terms of which were not disclosed - will see Kiadis transfer the technology needed to produce its Phase II product candidate ATIR, which is a cell-based treatment that allows stem cell transplantations from mismatched donors.

Kiadis told that: "The GRCBDS [German Red Cross] is highly experienced in manufacturing all kinds of blood-derived products and a perfect partner for this kind of product.

It added that: "Other CMOs would also be able to do this but might not have the same head-start of being involved in this area for decades​."

The firm also told us "rates charged by the GRCBDS are competitive and in the range of other international CMOs​."

Graft versus host disaes dealt with

Kiadis' ATIR is less a treatment than it is a way of providing sufferers of late-stage blood cancer with the possibility of receiving a transplant from an unmatched donor without the risk of graft-versus-host disease (GVHD) as the firm explained.

"The donor immune cells are are simply exposed to antigens from the patient in the culture flask to activate immuncells which would cause GvHD in the patient. These GvHD-eliciting cells are then specifically eliminated using Kiadis’ technology​."

When tech-transfer is completed later this year the GRCBDS will be responsible for the manufacture of ATIR from the starting materials - a process known as apheresis where the immune cells responsible for GVHD are removed. The final product, formulated ATIR frozen on liquid nitrogen, whill then be available for transplant.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more